Tazarotene foam, 0.1%, for the treatment of acne

Smith, Jaclyn A.; Narahari, Swetha; Hill, Denise S.; Feldman, Steven R.

doi:10.1517/14740338.2016.1117605

Cited by 12 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 Topical tazarotene as a 0.1% gel, 0.1% cream, or 0.1% foam is therapeutically effective. [19][20][21] A previous study has established the superior efficacy of tazarotene gel, 0.1%, over adapalene, 0.1%, in the management of acne. 22 Tazarotene cream, 0.1%, has been found to significantly improve macular acne scars compared with adapalene gel, 0.3%.…”

Section: Discussionmentioning

confidence: 99%

“…Because few studies have investigated the use of topical retinoids for acne scar management, a comparison evaluating the efficacy of tazarotene and other topical retinoids is not feasible. Moreover, although the evidence for the efficacy of tazarotene application in active acne is robust, 21,23,27,30 the evidence for the efficacy of microneedling therapy is based on studies using fractional radiofrequency microneedling devices. 31,32 Even though study participants show improvement in acne using these devices, it appears that this type of therapy must be continued to maintain the attained outcome.…”

Section: Discussionmentioning

confidence: 99%

“…The US Food and Drug Administration approved tazarotene, a third-generation topical acetylenic retinoid, for acne vulgaris in June 1997 . Topical tazarotene as a 0.1% gel, 0.1% cream, or 0.1% foam is therapeutically effective . A previous study has established the superior efficacy of tazarotene gel, 0.1%, over adapalene, 0.1%, in the management of acne .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars

Afra

Narang

et al. 2019

JAMA Facial Plast Surg

View full text Add to dashboard Cite

IMPORTANCE Evidence is robust for the effectiveness of microneedle therapy in the management of postacne atrophic scarring. A home-based topical treatment with an efficacy comparable to microneedling would be a useful addition in the armamentarium of acne scar management. OBJECTIVE To compare the efficacy of topical tazarotene gel, 0.1%, with microneedling therapy in the management of moderate to severe atrophic acne scars. DESIGN, SETTING, AND PARTICIPANTS Prospective, observer-blinded, active-controlled, randomized clinical trial with 6 months of follow-up conducted between June 2, 2017, and February 28, 2018, at a tertiary care hospital in India. Thirty-six patients with grade 2 to 4 facial atrophic postacne scars and without a history of procedural treatment of acne scars within the previous year were recruited. Analyses were conducted using data from the evaluable population. INTERVENTIONS Both halves of each participant's face were randomized to receive either microneedling or topical tazarotene therapy. Microneedling was conducted on 1 side of the face with a dermaroller having a needle length of 1.5 mm for a total of 4 sessions during the course of 3 months. Participants were instructed to apply topical tazarotene gel, 0.1%, to the other side of the face once every night during this same period. MAIN OUTCOMES AND MEASURES Patients were followed up at 3 and 6 months by a blinded observer, and improvements in acne scar severity based on Goodman and Baron quantitative and qualitative scores and a subjective independent dermatologist score (range, 0-10, with higher scores indicating better improvement) were assessed. Patient satisfaction was assessed using a patient global assessment score (ranging from 0 for no response to 10 for maximum improvement) at these follow-up visits. RESULTS There were 36 participants (13 men and 23 women; mean [range] age, 23.4 [18-30] years), and the median (interquartile range [IQR]) duration of acne was 6 (4-8) years. For the 34 participants included in the complete data analyses, the median (IQR) quantitative score for acne scar severity at the 6-month follow-up visit following treatment with either tazarotene (from a baseline of 8.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars

Afra

Narang

et al. 2019

JAMA Facial Plast Surg

View full text Add to dashboard Cite

show abstract

“…11 A concentração 0,1% é a única aprovada pela FDA, sendo a espuma adequada na acne moderada a severa em idade superior a 12 anos. 37…”

Section: Comedónicaunclassified

Opções Terapêuticas Farmacológicas na Acne vulgar

Freitas

Velho

2021

SPDV

View full text Add to dashboard Cite

A acne vulgar é uma patologia crónica da unidade pilossebácea caracterizada por polimorfismo cutâneo, sendo das mais prevalentes na adolescência. Pode originar sequelas físicas, como cicatrizes desfigurantes, e psicológicas, nomeadamente diminuição da qualidade de vida e função psicossocial. Assim, torna-se fundamental uma estratégia terapêutica eficaz de modo a promover a sua resolução e, simultaneamente, minimizar a presença destas sequelas. Atualmente, os fármacos disponíveis são diversos, obrigando, na sua seleção, à avaliação biopsicossocial do doente. Estudos recentes têm apontado novos agentes terapêuticos promissores, nomeadamente alternativas aos retinóides tópicos, isotretinoína oral, antiandrogénios orais e antibióticos. Estes poderão permitir uma redução da resistência antibiótica e consequente aumento da eficácia com redução substancial dos efeitos adversos. O melhor perfil de segurança e tolerabilidade poderá otimizar a abordagem terapêutica atual.

show abstract

“…Some variability in performance and patient acceptability of these conventional topical formulations has been demonstrated. For example, based on their review of the available literature up to 2016, Smith et al [78] concluded that the tazarotene 0.1% foam, that was approved by the FDA in 2012, has increased patient compliance and satisfaction compared to other topical tazarotene formulations.…”

Section: Targeted Topical Delivery Of Retinoids: Strategies To Impmentioning

confidence: 99%

Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems

et al. 2019

View full text Add to dashboard Cite

Acne vulgaris is a common inflammatory pilosebaceous condition that affects 80–90% of adolescents. Since the introduction of tretinoin over 40 years ago, topical retinoid products have been a mainstay of acne treatment. The retinoids are very effective in addressing multiple aspects of the acne pathology as they are comedolytic and anti-inflammatory, and do not contribute to antibiotic resistance or microbiome disturbance that can be associated with long-term antibiotic therapies that are a common alternative treatment. However, topical retinoids are associated with skin dryness, erythema and pain, and may exacerbate dermatitis or eczema. Thus, there is a clear need to target delivery of the retinoids to the pilosebaceous units to increase efficacy and minimise side effects in surrounding skin tissue. This paper reviews the current marketed topical retinoid products and the research that has been applied to the development of targeted topical delivery systems of retinoids for acne.

show abstract

Tazarotene foam, 0.1%, for the treatment of acne

Abstract: The foam vehicles may increase compliance and satisfaction in some patients and as retinoids are commonly first line acne treatments, this new topical retinoid foam may be a useful option for some acne patients.

Cited by 12 publications

References 11 publications

Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars

Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars

Opções Terapêuticas Farmacológicas na Acne vulgar

Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems

Contact Info

Product

Resources

About